2022 Short Course - Episodic Movement Disorder Phenotype in Children: Approach to Diagnosis, Review and Updates of Selected Conditions
(1)
Image For Activity Cover
Availability
On-Demand
Expires on 04/30/2024
Cost
ACMG Member: $100.00
Non-Member: $120.00
Postdoc/Trainee (M): $100.00
Postdoc/Trainee (NM): $120.00
Student (M): $100.00
Student (NM): $120.00
Credit Offered
4.5 CME (AMA) Credits
4.5 CME (Other) Credits
4.5 P.A.C.E. Credits

First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.

For technical support, please send an email to: education@acmg.net  or call 301-718-9603.

Or click on the "Help" icon on the left-hand side of your screen for more information.

Support Center Hours: Monday- Friday 9:00 am - 5:00 pm Eastern Time 

Date of Release: May 2, 2022
Expiration Date: April 30, 2024

Credits offered:  CME, P.A.C.E.®,

Estimated time for completion: 4.5 hours

Course must be completed by the expiration date

 

The episodic movement disorder phenotype often leads to diagnostic odysseys that end with the medical geneticist. In current practice, diagnosis is very late and patients with episodic movement disorders may reach the geneticist at any age. Despite a yield of 17%- 50% in confirmed neurogenetic diagnoses among patients with childhood-onset movement disorders in general, the average time to diagnosis was 11 years after symptom onset [PMID 30363430, 30283815]. A geneticist familiar with genetic causes of this phenotype can substantially improve patients’ care by making a timely diagnosis.

This practical, case-based session will broaden participants’ knowledge of neurogenetics by introducing key genetic and metabolic causes of episodic movement disorders beyond acute intoxication, as well as their implications for testing, prognosis, and treatment. At the end of the session, participants will be able to narrow the differential diagnosis of a patient with episodic movement disorder, select appropriate testing panels, and understand potential treatments.

An expert panel of neurogeneticists will present clinical cases, each followed by discussion of the patient’s condition and management. The disorders were selected to provide a broad overview of the diversity of movement disorder-associated genes:

  1. ADCY5­-related Dyskinesias (20 min): This gain-of-function disorder can involve paroxysmal chorea, dystonia, or myoclonus which can continue through the night, unlike most movement disorders. The presenter will be Dr. Fuki Hisama, the author of the GeneReview for this condition.
  2. SLC2A1-related movement disorders / GLUT1 deficiency syndrome (G1D) (20 min): The spectrum of neurological involvement includes exercise-induced dystonia and other non-epileptic movement disorders, which can present in adults. Cerebral energy deficiency can be directly treated using the ketogenic diet. The presenter will be Dr. Juan Pascual, the author of the GeneReview for this condition.
  3. Alternating hemiplegia of childhood (AHC) (20 min): This disorder caused due to pathogenic ATP1A3 variants is characterized by distinctive clinical features such as monocular nystagmus. Management of respiratory compromise during episodes of paralysis is important, as well as treatment of co-occurring epilepsy and potential use of flunarizine. The presenter will be Dr. Sho Yano, who has described atypical ATP1A3-associated phenotypes and conducts research on AHC.
  4. Neurometabolic Disorders with Episodic Movement Disorder Phenotypes (25 min): Pyruvate dehydrogenase complex deficiency and TANGO2-related recurrent metabolic crises with encephalomyopathy and cardiac arrhythmias can both present with intermittent movement disorders. Biochemical testing and/or the presence of metabolic crises can help reach the diagnosis but may not always occur during the initial few years with atypical phenotypes. The presenter will be Dr. Kuntal Sen, who has described the intermittent movement disorders in these conditions and conducts research on mitochondrial disorders [PMID 30650451, 33592356].

Target Audience:

Clinical Genetics

Learning Objectives:

At the conclusion of this session, participants should be able to:

  1. Describe the phenomenology of movement disorders
  2. Discuss the basic classification of pediatric movement disorders.
  3. ADCY5 related Dyskinesia: Identify clinical features that could suggest the diagnosis of ADCY5-related dyskinesia.
  4. GLUT1DS: Identify the phenomenology and assess whether treatment is needed for the movement events typical of Glucose transporter type I deficiency.
  5. GLUT1DS: Discuss the clinical heterogeneity of GLUT-1 related disorders.
  6. Alternating hemiplegia: Recognize the classic childhood-onset presentation of alternating hemiplegia as well as adult-onset rapid-onset dystonia-parkinsonism and variant phenotypes.
  7. Analyze other phenotypes associated with ATP1A3 including adult-onset rapid-onset dystonia-parkinsonism and cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorineural hearing loss.
  8. Compare biochemical and clinical features of metabolic disorders to those of other causes of intermittent movement disorders.
  9. Discuss a diagnostic approach for suspected inborn errors of metabolism presenting with movement disorders.

Moderator:

 

Andrea Gropman, MD, FACMG

Children's National Hospital

Presenter(s): 

Fuki Hisama MD, FAAN, FACMG

Seattle Cancer Care Alliance

Juan Pascual MD, PhD

University of Texas Southwestern Medical Center

Kuntal Sen MD, FACMG

Children's National Hospital

Lisa Emrick, MD

Baylor College of Medicine

 

Sho Yano MD, PhD

National Institutes of Health

Continuing Medical Education (CME AMA & CME Other)

Accreditation
The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Credit Designation

The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 4.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

P.A.C.E.® CEU's
ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program. This activity has been approved for a maximum of 4.5 P.A.C.E.® CEU’s. ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider #50-11878. This course is registered with CEBroker #20-908432.  ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.®

Claiming your Educational Credits

This activity consists of: View content, take a post-test, the test may be taken as often as necessary to achieve a passing score of 80% or better is required to receive credit.  If you do not achieve a passing score, the program will identify which questions you answered incorrectly so that you can review the module and try again. Complete the evaluation form.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

ACMG Education Policies

Please review the policies below regarding the ACMG Education program


All of the relevant financial relationships listed for these individuals have been mitigated.

Name

Program Committee Member

Presenter
Panelist
Moderator

Peer Reviewer

Financial Disclosure Relationship/Company

Barnett, Claudia

x

   

Nothing to disclose

Bernat, John

x

   

Advisory Board Member: Avrobio, BioMarin Pharmaceutical, Idorsia Pharmaceuticals, Pfizer, Protalix Biotherapeutics, Sangamo Therapeutics, Sanofi Genzyme, Takeda Pharmaceutical;  Grant/Research Support: Avrobio, BioMarin Pharmaceutical, Idorsia Pharmaceuticals, Pfizer,  Protalix Biotherapeutics, Sangamo Therapeutics, Sanofi Genzyme, Takeda Pharmaceutical

Berry, Susan

x

   

Reported disclosures and none are relevant to the content of this course.

Conboy, Erin

x

   

Nothing to disclose

Cusmano-Ozog, Kristina

x

   

Nothing to disclose

Dahlroth, Jane

x

   

Nothing to disclose

Eddleman, Keith

x

   

Reported disclosures and none are relevant to the content of this course.

Elsea, Sarah

x

   

Grant/Research Support: Rhythm Pharmaceuticals, PTC Therapeutics, Shire Genetic Therapies

Consultant: Dicerna, Enzyvant, Vanda Pharmaceuticals

Rhythm Pharmaceuticals and Shire Genetic Therapies grants and Dicerna, Enzyvant consultancies have ended

Emrick, Lisa

 

x

 

Nothing to disclose

Freire, Penelope

x

   

Nothing to disclose

Gambello, Michael

x

   

Nothing to disclose

Gropman, Andrea 

 

x

 

Nothing to disclose

Hisama, Fuki

 

x

 

Nothing to disclose

Hodge, Jennelle

x

   

Scientific advisor: Helogenika

Hoffman, Jodi

x

   

Nothing to disclose

King, Jennifer

x

   

Nothing to disclose

Kopp, Nathan

x

   

Nothing to disclose

Kulchak Rahm, Alanna 

x

   

Nothing to disclose

Mito, Yoshiko

x

   

Nothing to disclose

Meng, Su

 

 

x

Nothing to disclose

Muenke, Maximilian

x

   

Nothing to disclose

Mulvihill, John

 

 

x

Nothing to disclose

Niehaus, Annie 

 

 

x

Nothing to disclose

O'Shea, Jessica 

x

   

Nothing to disclose

Pal, Tuya

x

   

Nothing to disclose

Parikh, Aditi

 

 

x

Nothing to disclose

Pascual, Juan 

 

x

 

Nothing to disclose

Radford, Jane

x

   

Nothing to disclose

Rowsey, Ross

x

   

Nothing to disclose

Sen, Kuntal 

 

x

 

Nothing to disclose

Slavotinek, Anne

 

 

x

Nothing to disclose

Stover, Samantha

x

   

Nothing to disclose

Tischkowitz, Marc 

x

   

Nothing to disclose

Wick, Myra

x

   

Nothing to disclose

Williams, Eli

x

   

Nothing to disclose

Williams, Marc

x

   

Nothing to disclose

Yano, Sho

 

x

 

Nothing to disclose

Zepeda Mendoza, Cinthya

x

   

Nothing to disclose

© 2024 American College of Medical Genetics and Genomics. All rights reserved.

Powered By